Torrent Pharmaceuticals Limited (TORNTPHARM.NS)
NSE · INR · Healthcare · Drug Manufacturers - Specialty & Generic
₹4,625.00 (+1.65%) as of
Key statistics
- Market cap
- 1.76T
- P/E (TTM)
- 78.12
- Forward P/E
- 50.91
- EPS (TTM)
- 59.20
- Dividend yield
- 0.84%
- 52-week range
- 3,532.60 – 5,250.00
- Beta
- 0.14
- Revenue (TTM)
- 174B
- Profit margin
- 12.21%
- Analyst target
- ₹5,482.43
- Volume
- 319.52k
About Torrent Pharmaceuticals Limited
Torrent Pharmaceuticals Limited engages in the research, development, manufacturing, marketing, and distribution of branded and generic pharmaceutical formulations in India, the United States, Brazil, Germany, Malta, and internationally. The company offers products in various therapeutic areas, including anti-diabetic, anti-microbial, cardiovascular, CNS, urology, gynecology, oncology, gastro-intestinal, nephrology, neuro-psychiatric, dermatology, pulmonology, pediatric treatments, nutritional, pain management, anti-infective, and miscellaneous, as well as vitamins, minerals, and nutrients. It also provides contract manufacturing services. The company offers its products under Tedibar, Shelcal, Unienzyme, ProZuca, and Ahaglow brands. The company was formerly known as Trinity Laboratories and changed its name to Torrent Pharmaceuticals Limited in 1971. The company was founded in 1959 and is based in Ahmedabad, India. Torrent Pharmaceuticals Limited is a subsidiary of Torrent Investments Private Limited.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Headquarters
- Ahmedabad, India
- Employees
- 18,258
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.